We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Liquid Biopsies Offer New Hope for Treatment and Tracking of Ovarian Cancer

By LabMedica International staff writers
Posted on 01 Aug 2016
Print article
Image: Researchers have found that DNA sequence analysis of blood samples from an initial set of ovarian cancer patients enabled detection of cancer recurrence long before a tumor reappears in analysis of tissue biopsies, suggesting that use of liquid biopsies may overcome obstacles to early detection and monitoring posed by current tumor tissue-based tests (Photo courtesy of the Mayo Clinic).
Image: Researchers have found that DNA sequence analysis of blood samples from an initial set of ovarian cancer patients enabled detection of cancer recurrence long before a tumor reappears in analysis of tissue biopsies, suggesting that use of liquid biopsies may overcome obstacles to early detection and monitoring posed by current tumor tissue-based tests (Photo courtesy of the Mayo Clinic).
Researchers are developing a new approach that could enable early detection, monitoring, and treatment for ovarian cancer (OC) that reoccurs in patients in remission: they found that liquid biopsies from blood tests and DNA sequencing can detect OC recurrence long before a tumor reappears.

OC tumors often cannot be detected until the late stages. Most patients go into remission after initial treatment, but the tumor returns 75% of the time and returning OC tumors typically do not respond to chemotherapy.

The research was performed by a Mayo Clinic (Rochester, MN, USA) team led by George Vasmatzis, PhD, Department of Laboratory Medicine and Pathology. “With liquid biopsies, we don’t have to wait for tumor growth to get a DNA sample,” said Dr. Vasmatzis, “This important discovery makes it possible for us to detect recurrence of the disease earlier than other diagnostic methods. We can repeat liquid biopsies to monitor the progression of the cancer.”

The study was done on 10 patients in advanced stages of OC, comparing DNA from the liquid blood biopsies to tumor tissue DNA samples. Mate-pair sequencing, an inexpensive whole-exome sequencing that can reveal genetic changes that contribute to tumor growth, was used.

“In this study, the blood drawn before and after surgery and the surgical tissue was used to identify DNA fragments with abnormal [chromosomal] junctions that can only be seen in this patient’s tumor DNA,” explained Dr. Vasmatzis, “Next-generation mate-pair sequencing was used to identify specific DNA changes of the tumor to create an individualized monitoring panel for liquid biopsy. This allows us to shape treatment to the individual patient rather than using a standard treatment that may not work for everyone.”

Individualized tumor-specific primer panels of aberrant chromosomal junctions were identified for each case and detected by qPCR within the cell-free DNA (cfDNA). When post-surgery DNA matched that of the tumor (circulating tumor DNA [ctDNA]), patients were later found to have had a recurrence of OC. However, when the post-surgery DNA did not match the DNA of the tumor, patients were found to be in remission. The findings suggest that a primer panel for individualized chromosomal junctions derived from tumor DNA could be effective for monitoring cancer patients for relapse and therapeutic efficacy using cfDNA.

The study, by Harris FR et al, was published July 20, 2016, in the journal Scientific Reports.

Related Links:
Mayo Clinic


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.